Medullary thyroid cancer is much less common than papillary or follicular types, occurring in 3% to 5% of all thyroid cancers. It is also more aggressive than those types. This type can metastasize to ...

The following is a summary of “Disparities in Postoperative Adjuvant Therapy Utilization and Factors Impacting Survival Among ...

Foscenvivint is under clinical development by Eisai and currently in Phase I for Anaplastic Thyroid Cancer. According to GlobalData, Phase I drugs for Anaplastic Thyroid Cancer have an 89% phase ...

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a ...

Foscenvivint is under development for the treatment of HCV or HBV or NASH-induced decompensated cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, ch ...

With 22 new cases recorded in 2022, thyroid cancer was ranked the 12th most prevalent cancer in The Bahamas that year, according to a report published by the Global Cancer ...

Diana Lynne Key, age 67, of Altamont Illinois, passed away from anaplastic thyroid cancer on May 16, 2024, after courageously battling multiple debilitating illnesses for the previous 5 years. Her ...

AffyImmune Therapeutics, a clinical-stage biotechnology company committed to developing its novel, first-in-class ICAM-1 ...

Barb Sabin, of Fort Lauderdale, went home to be with the Lord on September 16, 2024 after a courageous battle with Anaplastic Thyroid Cancer. Barb was born in Peoria, Illinois on October 30, 1935 too ...

Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab ...